688315 Stock Overview
Provides genomic services and solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 688315 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Novogene Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.45 |
| 52 Week High | CN¥23.56 |
| 52 Week Low | CN¥9.03 |
| Beta | 0.81 |
| 1 Month Change | 1.20% |
| 3 Month Change | 47.64% |
| 1 Year Change | -40.43% |
| 3 Year Change | -65.83% |
| 5 Year Change | n/a |
| Change since IPO | -50.91% |
Recent News & Updates
Recent updates
Earnings Working Against Novogene Co., Ltd.'s (SHSE:688315) Share Price
Sep 27
Some Confidence Is Lacking In Novogene Co., Ltd. (SHSE:688315) As Shares Slide 26%
Jun 07Time To Worry? Analysts Are Downgrading Their Novogene Co., Ltd. (SHSE:688315) Outlook
Apr 17Estimating The Fair Value Of Novogene Co., Ltd. (SHSE:688315)
Mar 25Shareholder Returns
| 688315 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -6.2% | -4.4% | -2.7% |
| 1Y | -40.4% | -17.9% | 11.8% |
Return vs Industry: 688315 underperformed the CN Life Sciences industry which returned -17.9% over the past year.
Return vs Market: 688315 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 688315 volatility | |
|---|---|
| 688315 Average Weekly Movement | 10.2% |
| Life Sciences Industry Average Movement | 10.2% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688315 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688315's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2,144 | Ruiqiang Li | www.novogene.com |
Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus CR, a gene coverage for hereditary cancer screening; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples.
Novogene Co., Ltd. Fundamentals Summary
| 688315 fundamental statistics | |
|---|---|
| Market cap | CN¥5.46b |
| Earnings (TTM) | CN¥187.24m |
| Revenue (TTM) | CN¥2.09b |
29.1x
P/E Ratio2.6x
P/S RatioIs 688315 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688315 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.09b |
| Cost of Revenue | CN¥1.21b |
| Gross Profit | CN¥885.56m |
| Other Expenses | CN¥698.32m |
| Earnings | CN¥187.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 42.33% |
| Net Profit Margin | 8.95% |
| Debt/Equity Ratio | 0% |
How did 688315 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield10%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 09:10 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novogene Co., Ltd. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| null null | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |